You are here

HEPATIC DIRECTED ANTIVIRAL AGENTS

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 18969
Amount: $50,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 1992
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
61 Mooney Street
Cambridge, MA 02138
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Philip M Enriquez
 (617) 497-2070
Business Contact
Phone: () -
Research Institution
N/A
Abstract

THE OBJECT OF THIS RESEARCH IS TO DEVELOP AN ANTI-HEPATITIS B VIRUS PRO-DRUG WHICH WILL CONCENTRATE IN THE INFECTED LIVER TISSUE BY BINDING THE HEPATIC ASIALOGLYCOPROTEIN RECEPTOR AND RELEASING THE ACTIVE FORM OF THE DRUG IN THE HEPATOCYTE. TOWARD THIS END, A NUMBER OF ADENOSINE ARABINOFURANOSIDE/ARABINOGALACTAN CONJUGATES WILL BE SYNTHESIZED. THE CONJUGATES WILL BE EVALUATED AS SUITABLE PRODRUGS BY SEVERAL CRITICAL TESTS. INTERACTION WITH THE HEPATICASIALOGLYCOPROTEIN RECEPTOR IN VITRO WILL BE DETERMINED IN A COMPETITIVE BINDING ASSAY USING ISOLATED RAT HEPATOCYTES. THE RELEASE OF ADENOSINE ARABINOFURANOSIDE, OR IN SOME INSTANCES, ITS ALSO ACTIVE 5 MONOPHOSPHATE DERIVATIVE, WILL BE MEASURED IN VITRO ALSO USING A HEPATOCYTE CELL CULTURE A PRELIMINARY TOXICOLOGICAL EXAMINATION OF THE CONJUGATE CONSIDERED MOST SUITABLE AS A PRO-DRUG WILL BE CONDUCTED. THE RESEARCH IS EXPECTED TO LEAD TO AN ANTIVIRAL PRO-DRUG OF ADENOSINE ARABINOFURANOSIDE POSSESSING A GREATER POTENCY AND LOWERTOXICITY RELATIVE TO THE FREEDRUG.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government